Day One Biopharmaceuticals, Inc vs Merck & Company, Inc. — Stock Comparison

DAWN
Day One Biopharmaceuticals, Inc
$21.53
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 4.5/10

Q·Score Breakdown

4.5
Bearish
Overall
6.7
Neutral
0.5
Quality
6.2
9.2
Health
7
7.3
Growth
6.2
3.7
Valuation
7.2
2.5
Sentiment
7.1
DAWN

Clean balance sheet with low leverage (0.0× debt-to-equity).

currently unprofitable (-68% margin).

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

HOLD
Target $21.50 (-0.1%)
6 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

DAWN
MRK
Trailing P/E
31.5×
-112.4×
Forward P/E
11.5×
-67.8%
Profit Margin
13.6%
89.1%
Gross Margin
76.6%
-22.7%
ROE
83.9%
Revenue Growth
4.9%
Earnings Growth
-1.75
Beta
0.28
Price / Book
$2.2B
Market Cap
$277.0B
$6 – $22
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →